Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia

A. W. Bseiso, H. M. Kantarjian, J. Q. Guo, J. Cortes, M. Talpaz, C. Koller, M. AlBitar, M. Keating, R. Arlinghaus

Research output: Contribution to journalArticle

Abstract

Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) constitutes 15-35% of all ALL in adults. Its detection is prognostically significant. The Ph abnormality is usually detected through standard cytogenetic analysis but 20-30% of patients have insufficient metaphases (IM) with such analysis. To detect the BCR-ABL oncoprotein in peripheral blood specimen of patients with ALL at the time of diagnosis and at follow-up, a new sensitive technique of enhanced chemiluminescence Western blot (ECL-WB) analysis was investigated. Among 41 patients with newly diagnosed ALL, nine were Ph positive by cytogenetic studies; they were also BCR-ABL positive according to ECL-WB. Eight had p190 disease, and one had p210 disease. Among the 16 patients with IM, none demonstrated the oncoprotein through ECL-WB or through simultaneous Southern blot (SB) for p210 rearrangement. Follow-up studies were available for seven patients: four had detectable protein and three of them relapsed 4-20 weeks later; three had undetectable protein and one of them (who had low level protein at the time of diagnosis) relapsed 11 weeks later. Although none of the patients with IM at diagnosis had detectable protein according to ECL-WB, this was probably due to the small number of patients studied. One patient with IM studied at follow-up demonstrated the protein by ECL-WB. In summary, we describe a technique that is useful in the detection of p190/p210 ALL at diagnosis. It is less time consuming, and more cost effective than standard chromosome banding techniques. It may also detect the oncoprotein in cases with IM. Although a larger number of patients should be studied to prove its clinical usefulness, this technique may also be of value for monitoring residual disease at follow-up.

Original languageEnglish (US)
Pages (from-to)1583-1587
Number of pages5
JournalLeukemia
Volume11
Issue number9
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Metaphase
Luminescence
Western Blotting
Proteins
Oncogene Proteins
Chromosome Banding
Cytogenetic Analysis
Southern Blotting
Cytogenetics
Costs and Cost Analysis

Keywords

  • Acute lymphocytic leukemia
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bseiso, A. W., Kantarjian, H. M., Guo, J. Q., Cortes, J., Talpaz, M., Koller, C., ... Arlinghaus, R. (1997). Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia, 11(9), 1583-1587. https://doi.org/10.1038/sj.leu.2400752

Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. / Bseiso, A. W.; Kantarjian, H. M.; Guo, J. Q.; Cortes, J.; Talpaz, M.; Koller, C.; AlBitar, M.; Keating, M.; Arlinghaus, R.

In: Leukemia, Vol. 11, No. 9, 01.01.1997, p. 1583-1587.

Research output: Contribution to journalArticle

Bseiso, AW, Kantarjian, HM, Guo, JQ, Cortes, J, Talpaz, M, Koller, C, AlBitar, M, Keating, M & Arlinghaus, R 1997, 'Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia', Leukemia, vol. 11, no. 9, pp. 1583-1587. https://doi.org/10.1038/sj.leu.2400752
Bseiso, A. W. ; Kantarjian, H. M. ; Guo, J. Q. ; Cortes, J. ; Talpaz, M. ; Koller, C. ; AlBitar, M. ; Keating, M. ; Arlinghaus, R. / Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. In: Leukemia. 1997 ; Vol. 11, No. 9. pp. 1583-1587.
@article{8ea0707105454b91a69448154dab19f3,
title = "Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia",
abstract = "Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) constitutes 15-35{\%} of all ALL in adults. Its detection is prognostically significant. The Ph abnormality is usually detected through standard cytogenetic analysis but 20-30{\%} of patients have insufficient metaphases (IM) with such analysis. To detect the BCR-ABL oncoprotein in peripheral blood specimen of patients with ALL at the time of diagnosis and at follow-up, a new sensitive technique of enhanced chemiluminescence Western blot (ECL-WB) analysis was investigated. Among 41 patients with newly diagnosed ALL, nine were Ph positive by cytogenetic studies; they were also BCR-ABL positive according to ECL-WB. Eight had p190 disease, and one had p210 disease. Among the 16 patients with IM, none demonstrated the oncoprotein through ECL-WB or through simultaneous Southern blot (SB) for p210 rearrangement. Follow-up studies were available for seven patients: four had detectable protein and three of them relapsed 4-20 weeks later; three had undetectable protein and one of them (who had low level protein at the time of diagnosis) relapsed 11 weeks later. Although none of the patients with IM at diagnosis had detectable protein according to ECL-WB, this was probably due to the small number of patients studied. One patient with IM studied at follow-up demonstrated the protein by ECL-WB. In summary, we describe a technique that is useful in the detection of p190/p210 ALL at diagnosis. It is less time consuming, and more cost effective than standard chromosome banding techniques. It may also detect the oncoprotein in cases with IM. Although a larger number of patients should be studied to prove its clinical usefulness, this technique may also be of value for monitoring residual disease at follow-up.",
keywords = "Acute lymphocytic leukemia, Philadelphia chromosome",
author = "Bseiso, {A. W.} and Kantarjian, {H. M.} and Guo, {J. Q.} and J. Cortes and M. Talpaz and C. Koller and M. AlBitar and M. Keating and R. Arlinghaus",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/sj.leu.2400752",
language = "English (US)",
volume = "11",
pages = "1583--1587",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia

AU - Bseiso, A. W.

AU - Kantarjian, H. M.

AU - Guo, J. Q.

AU - Cortes, J.

AU - Talpaz, M.

AU - Koller, C.

AU - AlBitar, M.

AU - Keating, M.

AU - Arlinghaus, R.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) constitutes 15-35% of all ALL in adults. Its detection is prognostically significant. The Ph abnormality is usually detected through standard cytogenetic analysis but 20-30% of patients have insufficient metaphases (IM) with such analysis. To detect the BCR-ABL oncoprotein in peripheral blood specimen of patients with ALL at the time of diagnosis and at follow-up, a new sensitive technique of enhanced chemiluminescence Western blot (ECL-WB) analysis was investigated. Among 41 patients with newly diagnosed ALL, nine were Ph positive by cytogenetic studies; they were also BCR-ABL positive according to ECL-WB. Eight had p190 disease, and one had p210 disease. Among the 16 patients with IM, none demonstrated the oncoprotein through ECL-WB or through simultaneous Southern blot (SB) for p210 rearrangement. Follow-up studies were available for seven patients: four had detectable protein and three of them relapsed 4-20 weeks later; three had undetectable protein and one of them (who had low level protein at the time of diagnosis) relapsed 11 weeks later. Although none of the patients with IM at diagnosis had detectable protein according to ECL-WB, this was probably due to the small number of patients studied. One patient with IM studied at follow-up demonstrated the protein by ECL-WB. In summary, we describe a technique that is useful in the detection of p190/p210 ALL at diagnosis. It is less time consuming, and more cost effective than standard chromosome banding techniques. It may also detect the oncoprotein in cases with IM. Although a larger number of patients should be studied to prove its clinical usefulness, this technique may also be of value for monitoring residual disease at follow-up.

AB - Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) constitutes 15-35% of all ALL in adults. Its detection is prognostically significant. The Ph abnormality is usually detected through standard cytogenetic analysis but 20-30% of patients have insufficient metaphases (IM) with such analysis. To detect the BCR-ABL oncoprotein in peripheral blood specimen of patients with ALL at the time of diagnosis and at follow-up, a new sensitive technique of enhanced chemiluminescence Western blot (ECL-WB) analysis was investigated. Among 41 patients with newly diagnosed ALL, nine were Ph positive by cytogenetic studies; they were also BCR-ABL positive according to ECL-WB. Eight had p190 disease, and one had p210 disease. Among the 16 patients with IM, none demonstrated the oncoprotein through ECL-WB or through simultaneous Southern blot (SB) for p210 rearrangement. Follow-up studies were available for seven patients: four had detectable protein and three of them relapsed 4-20 weeks later; three had undetectable protein and one of them (who had low level protein at the time of diagnosis) relapsed 11 weeks later. Although none of the patients with IM at diagnosis had detectable protein according to ECL-WB, this was probably due to the small number of patients studied. One patient with IM studied at follow-up demonstrated the protein by ECL-WB. In summary, we describe a technique that is useful in the detection of p190/p210 ALL at diagnosis. It is less time consuming, and more cost effective than standard chromosome banding techniques. It may also detect the oncoprotein in cases with IM. Although a larger number of patients should be studied to prove its clinical usefulness, this technique may also be of value for monitoring residual disease at follow-up.

KW - Acute lymphocytic leukemia

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=0030876188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030876188&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2400752

DO - 10.1038/sj.leu.2400752

M3 - Article

C2 - 9305617

AN - SCOPUS:0030876188

VL - 11

SP - 1583

EP - 1587

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -